|
Quotes & Info
|
| MYGN > SEC Filings for MYGN > Form 8-K on 29-Apr-2009 | All Recent SEC Filings |
29-Apr-2009
Other Events, Financial Statements and Exhibits
On April 27, 2009, Myriad Genetics, Inc. ("Myriad"), announced the launch of OnDose™, the Company's seventh molecular diagnostic product. OnDose™ utilizes a unique, proprietary technology to measure a cancer patient's exposure to the chemotherapy drug 5-Fluorouracil (5-FU), to help oncologists adjust and optimize dosing to maximize efficacy and reduce toxicity. The price of each test is expected to be $300 and will be sold through Myriad's 150-person oncology sales force.
The press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.
(d) Exhibits.
99.1 Press release dated April 27, 2009.
Page 2 of 4 pages
|
|